Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ImmunoPulse IL-12 in Merkel Cell Carcinoma
NCT01440816Phase 2Completed
- Sponsor
- OncoSec Medical
- Start
- Jan 2012
- Primary completion
- Apr 2015
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
A Phase 2 trial of tavokinogene telseplasmid in Merkel cell carcinoma (MCC), sponsored by OncoSec Medical. Started Jan 2012; status: completed.
02
Drugs
tavokinogene telseplasmid
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT01440816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01440816.